All News

As artificial intelligence becomes commonplace in medical practice, officials are gradually uncovering significant safety risks.

By late February 2026, national data from the CDC reveal a test positivity rate of 9.1%, the highest recorded for the entire season at that point.

With value-based care initiatives on the rise in the US health care system, one partnership in Ohio is showing early signs of significant success.

CMS pilots BALANCE and GLP-1 Bridge models to widen Medicare/Medicaid obesity drug coverage, spotlighting pharmacists’ role in access and safe therapy.

Exploring data across a variety of income settings, researchers conduct a review of invasive pneumococcal disease carriage, cases, and their associations.

A PQA program shows how value-based pharmacy contracts, shared metrics, and better data boost immunizations and patient outcomes beyond dispensing.

Episode 10 explores recent guideline changes in clinicians’ management of dyslipidemia, highlighting much more than a few updated recommendations.

In part 2, Kevin Day, PharmD, breaks down the Pharmacy Quality Rewards Program and its push toward value-based care in pharmacy practice.

As accessible and trusted health care providers, pharmacists have important roles to play in helping patients mitigate the impact of heat on their health.

GLP-1 prescriptions surge to nearly 8% of fills, fueled by weight-loss demand.

With continued pressure for federal action regarding the abortion drug mifepristone, SCOTUS blocked a previous decision that would limit the pill’s access.

FDA clears Langlara interchangeable insulin glargine, enabling pharmacy substitution for Lantus and widening affordable basal insulin access.

Because pharmacists can review both prescription and refill histories, they are uniquely positioned to spot patterns of underuse or overuse of allergy and asthma medications.

Despite WHO officials stating that risks from the outbreak remain low, experts are acting urgently to uncover details and provide support.

Kevin Day, PharmD, provides insight into his role in the Pharmacist Quality Rewards Program and what it’s doing for patients in his community.

The FDA expands Auvelity for Alzheimer-related agitation, offering a first nonantipsychotic option backed by trials.

Utilizing colleges and schools of pharmacy, researchers explorensolutions to the growing challenges affecting community pharmacy.

Drug pricing rules reshape pharmacy and manufacturer strategies, as transparency grows and 340B reforms intensify scrutiny.

Among community pharmacies and their patients, researchers explore the power of protected learning time for improving services and outcomes.

With its capabilities improving rapidly in the health care space, technology and pharmacy experts discuss AI’s future place in pharmacy practice as further developments are released.

Specialty pharmacy shifts toward holistic, empathetic care, easier oral therapies, and wider community access to advanced cell and gene treatments.

Pharmacy leaders face rapid change, which can boost agility and automate repetitive tasks.

These discussions focused on gaps in artificial intelligence, community-based advanced therapy, and demands of federal drug price negotiations.

Amid shifting vaccine recommendations and an evolving health care landscape, pharmacists continue to weather the storm as frontline community immunizers.

An exploration of community pharmacists’ perceptions of e-pharmacy, assessing whether they believe it’s a threat or benefit.

FDA approves Caplyta to prevent schizophrenia relapse, cutting risk 63% with a stable metabolic profile.

Community pharmacists can help manage worsening wounds, coordinate rural care teams, and overcome time and scope limits to improve healing.